HomeCompareRVXCF vs FCPT

RVXCF vs FCPT: Dividend Comparison 2026

RVXCF yields 2298.85% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVXCF wins by $36577739038.80M in total portfolio value
10 years
RVXCF
RVXCF
● Live price
2298.85%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36577739038.85M
Annual income
$33,694,466,973,692,370.00
Full RVXCF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — RVXCF vs FCPT

📍 RVXCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVXCFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVXCF + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVXCF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVXCF
Annual income on $10K today (after 15% tax)
$195,402.30/yr
After 10yr DRIP, annual income (after tax)
$28,640,296,927,638,510.00/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, RVXCF beats the other by $28,640,296,927,633,604.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVXCF + FCPT for your $10,000?

RVXCF: 50%FCPT: 50%
100% FCPT50/50100% RVXCF
Portfolio after 10yr
$18288869519.45M
Annual income
$16,847,233,486,849,072.00/yr
Blended yield
92.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

RVXCF
No analyst data
Altman Z
-94.1
Piotroski
1/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVXCF buys
0
FCPT buys
0
No recent congressional trades found for RVXCF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVXCFFCPT
Forward yield2298.85%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$36577739038.85M$49.1K
Annual income after 10y$33,694,466,973,692,370.00$5,775.28
Total dividends collected$36375156338.99M$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RVXCF vs FCPT ($10,000, DRIP)

YearRVXCF PortfolioRVXCF Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$240,585$229,885.06$11,401$700.92+$229.2KRVXCF
2$5,426,296$5,168,870.07$13,064$864.84+$5.41MRVXCF
3$114,761,014$108,954,877.01$15,051$1,072.48+$114.75MRVXCF
4$2,276,338,467$2,153,544,182.26$17,442$1,337.22+$2276.32MRVXCF
5$42,357,698,654$39,922,016,494.37$20,340$1,677.08+$42357.68MRVXCF
6$739,586,041,815$694,263,304,255.43$23,880$2,116.57+$739586.02MRVXCF
7$12,120,492,876,395$11,329,135,811,652.31$28,241$2,689.36+$12120492.85MRVXCF
8$186,486,946,005,072$173,518,018,627,329.40$33,660$3,442.07+$186486945.97MRVXCF
9$2,694,646,789,868,656$2,495,105,757,643,229.00$40,456$4,439.95+$2694646789.83MRVXCF
10$36,577,739,038,851,830$33,694,466,973,692,370.00$49,063$5,775.28+$36577739038.80MRVXCF

RVXCF vs FCPT: Complete Analysis 2026

RVXCFStock

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Full RVXCF Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this RVXCF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVXCF vs SCHDRVXCF vs JEPIRVXCF vs ORVXCF vs KORVXCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.